ABSTRACT
Patients with chronic kidney dysfunction (CKD) have abnormal coagulation function and impaired drug metabolism, resulting in increased bleeding risk and decreased drug clearance. Therefore, while receiving treatment, the prognosis of ischemic stroke patients with CKD is different from that of ischemic stroke patients without CKD. For patients with CKD who need anticoagulant treatment, the use of new anticoagulants without renal metabolism can achieve the same anticoagulant effect as warfarin, and the risk of bleeding is lower. When using antiplatelet drugs, due to the increased risk of bleeding in ischemic stroke patients with CKD, the clinical benefits and bleeding risk should be carefully weighed. Although CKD is not an absolute contraindication of intravenous thrombolysis or endovascular treatment in patients with acute ischemic stroke, attention should be paid to the influence of CKD on the increased risk of death in patients with ischemic stroke after treatment.